Antioxidant Treatment Associated with Sildenafil Reduces Monocyte Activation and Markers of Endothelial Damage in Patients with Diabetic Erectile Dysfunction: A Double-Blind, Placebo-Controlled Study

European Urology

Volumn 52, Issue 6, 2007, Pages 1768-1776

  Morano, Susanna ^a   Mandosi, Elisabetta ^a   Fallarino, Mara ^a   Gatti, Alessandra ^a   Tiberti, Claudio ^a   Sensi, Maurizio ^a   Gandini, Loredana ^a   Buchetti, Barbara ^b   Lenti, Luisa ^b   Jannini, Emmanuele Angelo ^c   Lenzi, Andrea ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Diabetes; Erectile dysfunction; Monocytes; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; INTERCELLULAR ADHESION MOLECULE 1; PADGEM PROTEIN; PROPIONYLCARNITINE; SILDENAFIL;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG POTENTIATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM INJURY; ERECTILE DYSFUNCTION; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; MALE; MONOCYTE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTIOXIDANTS; BIOLOGICAL MARKERS; CARNITINE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; ERECTILE DYSFUNCTION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; MONOCYTES; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; REACTIVE OXYGEN SPECIES; SULFONES;

EID: 35748977390     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.04.042     Document Type: Article

References (29)

1. De Angelis L., Martella M.A., Siniscalchi M., et al. Erectile and endothelial dysfunction in Type II diabetes: a possible link. Diabetologia 44 (2001) 1155-1160
2. Marfella R., Esposito K., Giunta R., et al. Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia. Circulation 101 (2000) 2247-2251
3. Seftel A.D., Vaziri N.D., Ni Z., et al. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology 50 (1997) 1016-1026
4. Bocchio M., Desideri G., Scarpelli P., et al. Endothelial cell activation in men with erectile dysfunction without cardiovascular risk factors and overt vascular damage. J Urol 171 (2004) 1601-1604
5. Omi H., Okayama N., Shimizu M., et al. Participation of high glucose concentrations in neutrophil adhesion and surface expression of adhesion molecules on cultured human endothelial cells: effect of antidiabetic medicines. J Diabetes Complications 16 (2002) 201-208
6. Usta M.F., Kendirci M., Gur S., et al. The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: preventive versus curative treatment. J Sex Med 3 (2006) 242-250
7. Gazzaruso C., Giordanetti S., De Amici E., et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 110 (2004) 22-26
8. Solomon H., Man J.W., Wierzbicki A.S., and Jackson G. Relation of erectile dysfunction to angiographic coronary artery disease. Am J Cardiol 91 (2003) 230-231
9. Ignaro L.J., Bush P.A., Buga G.M., et al. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 170 (1990) 843-850
10. Rajfer J., Aronson W.J., Bush P.A., Dorey F.J., and Ignarro L.J. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 326 (1992) 90-94
11. Rendell M.S., Rajfer J., Wicker P.A., and Smith M.D. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Diabetes Study Group. JAMA 281 (1999) 421-426
12. Retter A.S. Carnitine and its role in cardiovascular disease. Hearth Dis 1 (1999) 108-113
13. Triggiani M., Oriente A., Golino P., et al. Inhibition of platelet activating factor synthesis in human neutrophils and platelets by proprionyl-L-carnitine. Biochem Pharmacol 58 (1999) 1341-1348
14. Orlandi A., Marcellini M., Pesce D., Calvani M., and Spagnoli L.G. Proprionyl-L-carnitine reduce intimal hyperplasia after injury in normocholesterolemic rabbit carotid artery by modulatine proliferation and caspase 3-dependent apoptosis of vascular smooth muscle cells. Atherosclerosis 160 (2002) 81-89
15. Santo S.S., Sergio N., Luigi D.P., et al. Effect of PLC on functional parameters and oxidative profile in type 2 diabetes associated PAD. Diabetes Res Clin Pract 72 (2006) 231-237
16. Felix C., Gillis M., Driedzic W.R., et al. Effects of propionyl-L-carnitine on isolated mitochondrial function in the reperfused diabetic rat heart. Diabetes Res Clin Pract 53 (2001) 17-24
17. Montorsi P., Ravagnani P.M., Galli S., et al. Association between erectile dysfunction and coronary artery disease: matching the right target with the right test in the right patient. Eur Urol 50 (2006) 721-731
18. Cipolletta C., Ryan K.E., Hanna E.V., and Trimble E.R. Activation of peripheral blood CD14+ monocytes occurs in diabetes. Diabetes 9 (2005) 2779-2786
19. Morano S., Gatti A., Mandosi E., et al. Circulating monocyte oxidative activity is increased in patients with type 2 diabetes and erectile dysfunction. J Urol 177 (2007) 655-659
20. NIH Consensus Conference. Impotence NIH Consensus Development Panel on Impotence. JAMA 7 (1993) 83-90
21. Buongiorno A.M., Sagratella E., Morelli S., Di Virgilio A., and Sensi M. Advanced glycosylation end product quantification: differently produced polyclonal antisera do not share the recognition of epitopes of different nature. Ann Ist Super Sanita' 38 (2002) 393-399
22. Aversa A., Bonifacio V., Moretti C., Frajese G., and Fabbri A. Re-dosing of prostaglandin-E1 versus prostaglandin-E1 plus phentolamine in male erectile dysfunction: a dynamic color power Doppler study. Int J Impot Res 12 (2000) 33-40
23. Kostis J.B., Jackson G., Rosen R., et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 15 (2005) 313-321
24. Gentile V., Vicini P., Prigiotti G., Koverech A., and Di Silverio F. Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes. Curr Med Res Opin 20 (2004) 1377-1384
25. Wespes E., Rammal A., and Garbar C. Sildenafil non-responders: haemodynamic and morphometric studies. Eur Urol 48 (2005) 136-139
26. Hatzimouratidis K., and Hatzichristou D. Phosphodiesterase type 5 inhibitors: the day after. Eur Urol 51 (2007) 75-89
27. Rubio-Aurioles E., Porst H., Eardley I., Goldstein I., and the Vardenafil-Sildenafil Comparator Study Group. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. J Sex Med 3 (2006) 1037-1049
28. Osterud B., and Bjorklid E. Role of monocytes in atherogenesis. Physiol Rev 83 (2003) 1069-1112
29. Teplyakov A.I. Endothelin-1 involved in systemic cytokine network inflammatory response at atherosclerosis. J Cardiovasc Pharmacol 44 Suppl 1 (2004) 274-275